The benefit of long-term interferon alfa therapy for symptomatic mixed cryoglobulinemia (cutaneous vasculitis/membranoproliferative glomerulonephritis) associated with chronic hepatitis C infection

Journal of Clinical Gastroenterology

Volumn 33, Issue 2, 2001, Pages 137-140

  Willson, R A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Chronic hepatitis C infection; Long term interferon alfa therapy; Symptomatic mixed cryoglobulinemia

Indexed keywords

ALPHA INTERFERON;

ADULT; AFFECTIVE NEUROSIS; AMNESIA; ARTHRALGIA; ARTICLE; CASE REPORT; CRYOGLOBULINEMIA; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; EYE IRRITATION; FATIGUE; FEMALE; HEPATITIS C; HUMAN; INSOMNIA; LONG TERM CARE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MYALGIA; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; RELAPSE; REMISSION; VASCULITIS; VIROLOGY;

ADULT; CRYOGLOBULINEMIA; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LONG-TERM CARE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME; VASCULITIS;

EID: 0034941561     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200108000-00009     Document Type: Article

References (36)

1. Interferon alfa therapy for chronic hepatitis C in special patient populations
2. Treatment of chronic viral hepatitis
3. Therapy of hepatitis C: Overview
4. Cryoglobulinemia in chronic liver disease: Role of hepatitis C virus and liver damage
5. Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinemia
6. Interferon alfa in mixed cryoglobulinemia patients: A randomized, crossover-controlled trial
7. Natural interferon alfa versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: A long-term randomized controlled study
8. Predictors of long-term response to high dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection
9. Effects of long-term course of alfa interferon in patients with chronic hepatitis C associated to mixed cryoglobulinemia
10. Response to interferon alfa treatment and disappearance of cryoglobulinemia in patients infected by hepatitis C virus
11. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy
12. Recommendations for evaluating the validity of quality of life claims for labeling and promotion
13. Sustained response to interferon alfa or to interferon alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinemia
14. Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis
15. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus
16. Clinicopathologic analysis and therapy in hepatitis C virus-associated nephropathy
17. Hepatitis C virus infection and acute or chronic glomerulonephritis: An epidemiological and clinical appraisal
18. Clinical toxicity of the interferons
19. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection
20. Hepatitis C virus infection and cryoglobulinemia
21. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha interferon therapy
22. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma
23. Ribavirin in hepatitis C related cryoglobulinemia
24. Beneficial effect of ribavirin on hepatitis C-associated cryoglobulinemia after liver transplantation
25. Effects of ribavirin on hepatitis C associated nephrotic syndrome in four liver transplant recipients
26. Inhibition of immune functions by antiviral drugs
27. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus
28. Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes
29. Interferon alfa and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia
30. Current therapy for chronic hepatitis C
31. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia
32. Results of interferon-alfa therapy in patients with chronic myelogenous leukemia 60 years of age and older
33. Neurotoxicity of interferon-α
34. Persistent neurotoxicity of systemically administered interferon-alfa
35. Side effects of alpha interferon in chronic hepatitis C
36. Side effects of alpha interferon